Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

NCT01444339

Pneumococcal Infections Streptococcus Pneumoniae Infections Pneumococcal Pneumonia

COMPLETED PHASE1

Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

NCT00560950

Pneumococcal Infection

COMPLETED PHASE3

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677

Streptococcus Pneumoniae

RECRUITING PHASE1

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

NCT01444352

Pneumococcal Infections Streptococcus Pneumoniae Infections Pneumococcal Pneumonia

COMPLETED PHASE1

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

NCT05092386

Pneumococcal Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Collect serum with antibody levels capable of killing pneumococcal bacteria from healthy prevaccinated adults to develop OPA assays for the 13 serotypes in 13-valent pneumococcal conjugate vaccine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All subjects

Group Type OTHER

Large volume blood draw

Intervention Type PROCEDURE

Large volume blood draw

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Large volume blood draw

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults 18-70 years of age
* Must have received 23vPS pneumococcal vaccine

Exclusion Criteria

* Bleeding diathesis
* Pregnancy
* Chronic disease which could be worsened by donating blood
* Receipt of blood, blood products or immune globulin within six months

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes